FOSUN HEALTH Logo

Type 1 Diabetes Prevention

catalogue

Type 1 Diabetes Prevention

Type 1 Diabetes Prevention

Prevention is the honest word this page must start with: there is not yet a way to stop the immune attack once it has begun, and no confirmed way to keep it from beginning. What does exist is prediction — and prediction has become genuinely useful. A blood test can find Type 1 diabetes years before the first symptom, place it on the official staging ladder, and change everything about how the disease arrives: a child found at stage 1 is monitored rather than ambushed, starts insulin before ketoacidosis rather than during it, and — in the published programme — enters evaluation with exactly the profile reported to respond best.

What prevention honestly means today

No lifestyle measure prevents Type 1 diabetes, and any page suggesting otherwise is describing Type 2. The immune attack, once running, has not yet been stopped by anything proven — which is why this page is about predicting rather than preventing. That is not a small consolation prize: the diagnosis everyone fears is not the disease itself but the way it arrives, at night, in an emergency department, with ketoacidosis. Early detection changes the arrival, and the arrival is most of the trauma.

Who should be screened, and what the test is

Screening means testing people without symptoms for islet autoantibodies — the fingerprints described on the causes page. The people it makes most sense for are the close relatives of patients: siblings, children and parents, where the background risk, though small in absolute terms, is many times the population rate, and where a positive result has a clear follow-up pathway. The test itself is a single blood draw covering the antibody panel — GAD65, IA-2, ZnT8 and their colleagues — and is repeated on a schedule, because antibodies can appear over time.

Two or more positive antibodies is the accepted threshold for stage 1, and it is at that point that the result stops being a statistic and becomes a plan.

What a stage 1 finding changes

A child at stage 1 feels nothing and needs no insulin. What they get instead is the machinery that prevents the emergency diagnosis: periodic glucose and HbA1c monitoring to catch the transition to stage 2, education for the family on the four Ts long before they appear, a written sick-day and ketone plan, and a relationship with a diabetes team established in daylight rather than in crisis. International data is unambiguous on the value: children found through screening rarely present in ketoacidosis, and the first weeks of treatment are a different experience from the emergency version.

The third change is the one specific to this cluster: stage, and the C-peptide that travels with it, is the eligibility frame of the published HIM programme — early diagnosis with C-peptide above 0.5 ng/ml is the position in which insulin discontinuation was reported. Screening is therefore not only about safety; it preserves the options that late diagnosis quietly closes.

The research frontier: delaying onset

Intervention at the pre-symptomatic stages is the active frontier. Internationally, an immunotherapy — teplizumab — has been approved in the United States to delay the onset of stage 3 Type 1 diabetes in screened, high-risk individuals, buying years of insulin-free life; it is a delay rather than a prevention, and access remains limited, but it proves the principle that the pre-symptomatic disease is actionable. Immune-modulation trials of other designs continue, and the integrative programme described in this cluster is itself part of that research conversation, with its published interim results reported at the earliest stages of remaining function.

What we advise, in one paragraph

For relatives of a patient: screen, and if the screen is negative, repeat it on the advised schedule. If antibodies are found, treat the staging pathway as good news badly worded — the disease was found while it was still quiet, and everything about the next years is now planned rather than reactive. For diagnosed patients: keep the C-peptide on the record at intervals, because remaining function is the number on which every future option, including the ones this cluster describes, depends. And for everyone: the four Ts belong on the family noticeboard, because the day someone in the house needs them is a day measured in hours.

Frequently Asked Questions

Can Type 1 diabetes be prevented?

Not yet, and this page does not pretend otherwise. No diet, supplement or lifestyle measure has been shown to stop the autoimmune attack from beginning or running its course. What can be done is earlier: antibody screening finds the disease years before symptoms, staging turns that knowledge into a planned start rather than an emergency, and onset-delaying therapy for high-risk screened individuals has been approved abroad. Prediction is today what prevention may become tomorrow.

Should my other children be screened even though they are well?

Yes — that is precisely who screening is for. The test is a blood draw for islet autoantibodies, the risk in siblings of a patient is several times the population rate, and a positive result places the child on the staging pathway years before any symptom. Most screens are reassuring. The ones that are not change the story in ways this page exists to explain: monitoring instead of ambush, and the preserved options that come with early diagnosis.

If my child is found at stage 1, will they need insulin straight away?

No. Stage 1 means antibodies are present and glucose is still normal — there is nothing for insulin to treat yet. What follows is scheduled monitoring for the move to stage 2, education, and a written ketone and sick-day plan. Insulin begins when glucose changes, and for screened children that beginning is typically planned, unhurried and free of the ketoacidosis that marks unscreened first diagnoses.

What is the point of keeping C-peptide on the record after diagnosis?

Because remaining islet function is the number every future option is measured against. It is the eligibility frame of the published HIM programme, reported above 0.5 ng/ml; it is how the honeymoon is distinguished from real recovery; and it is the baseline any future immune or regenerative therapy would be assessed against. The test is a simple blood draw, and a record that shows its trend over years is worth more than any single value.

Arrange screening, or read the staging pathway first

Tell us which relatives you would like screened, their ages, and the family history of diabetes. The team will explain what the antibody test involves, how results are staged, what a stage 1 finding would mean in practice, and how screening connects to the eligibility frame of the programme — in writing, before any test is booked.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*